Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Edgewise Therapeutics, Inc.
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/10/2023
8-K
Quarterly results
Docs:
"
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
"
07/14/2023
8-K
Quarterly results
06/16/2023
8-K
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs:
"
Common stock SALES AGREEMENT
",
"
Re: Registration Statement on Form S-3
"
05/11/2023
8-K
Quarterly results
Docs:
"
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
"
03/06/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
"
02/23/2023
8-K
Quarterly results
Docs:
"
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
"
11/03/2022
8-K
Quarterly results
09/14/2022
8-K
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
"
UNDERWRITING AGREEMENT
",
"
Follow-On Public Offering of Edgewise Therapeutics, Inc.
"
09/13/2022
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Investors & Media
",
"
Investors & Media
",
"
Updated Risk Factor Disclosure
"
08/04/2022
8-K
Quarterly results
Docs:
"
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
"
06/24/2022
8-K
Quarterly results
05/11/2022
8-K
Quarterly results
02/24/2022
8-K
Quarterly results
01/05/2022
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy
"
11/10/2021
8-K
Quarterly results
Docs:
"
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
"
10/28/2021
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose Study in Healthy Volunteers and Doses First Becker Muscular Dystrophy Patients
"
08/09/2021
8-K
Quarterly results
05/13/2021
8-K
Quarterly results
03/30/2021
8-K
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs:
"
Amended and Restated Certificate of Incorporation of the Registrant
",
"
Amended and Restated Bylaws of the Registrant
",
"
Press Release
"
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy